# CBIO catalysts: CRESCENT BIOPHARMA, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cbio/catalysts

> CRESCENT BIOPHARMA, INC. (CBIO) has 8 upcoming catalysts. The next is the SKB105 interim data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CBIO?

CRESCENT BIOPHARMA, INC. (CBIO) has 8 upcoming catalysts. The next is the SKB105 interim data readout, Q1 2027. SEC Form 10-Q: "In the first quarter of 2026, we initiated a global Phase 1/2 trial of CR-001 (the "ASCEND trial"), with initial data expected in the first quarter of 2027, and, through our partner Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun"), a Phase 1/2 trial of CR-003 (also known as SKB105) as a monotherapy in China, with proof-of-concept data expected in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/companies/cbio/catalysts)

Source: SEC Form 10-Q, accession 0001628280-26-073389, https://www.sec.gov/Archives/edgar/data/1253689/000162828026073389/cbio-20260930.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/cbio/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | CRESCENT BIOPHARMA, INC. |
| Ticker | CBIO (Nasdaq) |
| SEC CIK | 1253689 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/cbio |

## Cash runway

Cash $289.4M as of 2026-09-30; quarterly burn $26.9M; about 32.2 months of runway at that rate (XBRL company facts, accession 0001628280-26-073389).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2024 | [Uproleselan topline data readout](https://sec-api.dev/pdufa/uproleselan) | CBIO |  | completed, mixed | "In May 2024, we reported topline results from the Phase 3 trial, in which uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat, or ITT, population versus chemotherapy alone." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1253689/000155837025000948/glyc-20241231x10k.htm)) |
| July 29, 2025 | [CRESCENT BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/cbio/catalysts) | CBIO |  | completed | "Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828025036846/pressrelease-q22025.htm)) |
| November 6, 2025 | [CRESCENT BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/cbio/catalysts) | CBIO |  | completed | "Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828025049865/pressrelease-q32025.htm)) |
| Q1 2026 | [SKB105 trial start](https://sec-api.dev/pdufa/skb105) | CBIO | solid tumors | scheduled | "•Kelun-Biotech plans to initiate a Phase 1/2 trial of CR-003 (SKB105) in Greater China in the first quarter of 2026, with proof-of-concept data expected in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828025055221/exhibit992-cbiopressrelease.htm)) |
| Q1 2026 | [Ivonescimab trial start](https://sec-api.dev/pdufa/ivonescimab) | CBIO | solid tumors | scheduled | "We are thrilled with the engagement from clinicians who share our enthusiasm for CR-001 and plan to commence our global Phase 1 trial in patients with solid tumors in the first quarter of 2026 with initial data anticipated later next year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828025049865/pressrelease-q32025.htm)) |
| Feb 2026 | [KEYTRUDA® (pembrolizumab) trial start](https://sec-api.dev/pdufa/pembrolizumab) | CBIO |  | completed | "We initiated a global Phase 1/2 trial of CR-001 (the "ASCEND trial") in February 2026 and a Phase 1/2 trial of CR-003 as a monotherapy in the first quarter of 2026 in China through our partner, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1253689/000162828026028362/cbio-20260331.htm)) |
| Feb 2026 | [SKB105 trial start](https://sec-api.dev/pdufa/skb105) | CBIO |  | completed | "We initiated a global Phase 1/2 trial of CR-001 in February 2026, and a Phase 1/2 trial of CR-003 (also referred to as SKB105), an integrin beta-6 ("ITGB6")-directed ADC, as a monotherapy in the first quarter of 2026 in China through our partner, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun")." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1253689/000162828026048344/prospectussupplementfollow.htm)) |
| February 26, 2026 | [CRESCENT BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/cbio/catalysts) | CBIO |  | completed | "Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828026011988/pressrelease-q42025.htm)) |
| April 29, 2026 | [CRESCENT BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/cbio/catalysts) | CBIO |  | completed | "Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828026028386/pressrelease-livefile.htm)) |
| May 2026 | [SKB118 trial start](https://sec-api.dev/pdufa/skb118) | CBIO |  | completed | "◦In May 2026, Kelun-Biotech received Investigational New Drug (IND) approval from the Center for Drug Evaluation of the National Medical Products Administration for CR-001 (SKB118) for the treatment for advanced solid tumors, and subsequently commenced a Phase 1/2 monotherapy trial in China." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828026050805/pressrelease-livefile.htm)) |
| 2H 2026 | [SKB105 trial start](https://sec-api.dev/pdufa/skb105) | CBIO |  | scheduled | "•The Company expects to submit an IND for CR-002 in mid-2026 to support initiation of a planned Phase 1/2 trial in solid tumors in the second half of 2026, with proof-of-concept data expected in the second half of 2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1253689/000162828025055221/cbio-20251202.htm)) |
| July 30, 2026 | [CRESCENT BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/cbio/catalysts) | CBIO |  | completed | "Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828026050805/pressrelease-livefile.htm)) |
| November 12, 2026 | [CRESCENT BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/cbio/catalysts) | CBIO |  | completed | "Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828026073409/pressrelease-livefile.htm)) |
| Q1 2027 | [SKB105 interim data readout](https://sec-api.dev/pdufa/skb105) | CBIO |  | scheduled | "In the first quarter of 2026, we initiated a global Phase 1/2 trial of CR-001 (the "ASCEND trial"), with initial data expected in the first quarter of 2027, and, through our partner Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun"), a Phase 1/2 trial of CR-003 (also known as SKB105) as a monotherapy in China, with proof-of-concept data expected in the first quarter of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1253689/000162828026073389/cbio-20260930.htm)) |
| mid-2027 | [SKB118 interim data readout](https://sec-api.dev/pdufa/skb118) | CBIO | locally advanced or metastatic NSCLC | scheduled | "•A Phase 2 trial of CR-001 (SKB118) and sac-TMT in participants with locally advanced or metastatic NSCLC is ongoing with initial data expected in mid-2027;" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1253689/000162828026066006/cbio-20261015.htm)) |
| mid-2027 | [CRESCENT BIOPHARMA, INC. interim data readout](https://sec-api.dev/companies/cbio/catalysts) | CBIO | locally advanced or metastatic NSCLC | scheduled | "Initial data from a study in patients with locally advanced or metastatic NSCLC are expected in mid-2027 (Q2/Q3)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828026073409/pressrelease-livefile.htm)) |
| mid-2027 | [KEYTRUDA® (pembrolizumab) interim data readout](https://sec-api.dev/pdufa/pembrolizumab) | CBIO |  | scheduled | "We anticipate initiation of a CR-002 monotherapy clinical trial in 2026 as well as the first ADC combination trial with CR-001 with initial data anticipated in mid-2027 (second or third quarter)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1253689/000162828026028362/cbio-20260331.htm)) |
| 2H 2027 | [Sacituzumab tirumotecan interim data readout](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | CBIO | non-small cell lung cancer | scheduled | "We also initiated a global Phase 1/2 trial of CR-002 (the "APOLLO trial") in the fourth quarter of 2026, with initial data expected in the second half of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1253689/000162828026073389/cbio-20260930.htm)) |
| late 2027 | [SKB105 interim data readout](https://sec-api.dev/pdufa/skb105) | CBIO |  | scheduled | "A combination study of CR-003 and CR-001 is planned to initiate in the first half of 2027 with initial data anticipated by year-end 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828025055221/exhibit992-cbiopressrelease.htm)) |
| late 2027 | [CRESCENT BIOPHARMA, INC. interim data readout](https://sec-api.dev/companies/cbio/catalysts) | CBIO |  | scheduled | "A Phase 1/2 combination trial of CR-003 and CR-001 is expected to initiate in the first half of 2027, with initial data anticipated by year-end 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828026050805/pressrelease-livefile.htm)) |
| early 2028 | [TAXOL® (paclitaxel) trial start](https://sec-api.dev/pdufa/paclitaxel) | CBIO |  | scheduled | "Pending results and further interactions with regulators, the Company plans to initiate the first of multiple Phase 3 trials of CR-001 in early 2028." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1253689/000162828026066006/cbio-20261015.htm)) |

## Drugs

- [SKB105](https://sec-api.dev/pdufa/skb105): solid tumors
- [SKB118](https://sec-api.dev/pdufa/skb118): locally advanced or metastatic nsclc
- [Uproleselan](https://sec-api.dev/pdufa/uproleselan): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cbio/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CBIO catalysts: CRESCENT BIOPHARMA, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cbio/catalysts

```bibtex
@misc{secapidev_companies_cbio_catalysts_20261116,
  title        = {CBIO catalysts: CRESCENT BIOPHARMA, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cbio/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cbio_catalysts_20261116","title":"CBIO catalysts: CRESCENT BIOPHARMA, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cbio/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
